Live: Clinical Pearls: Hot Topics in Osteoporosis

    Sunday, March 21, 2021 
    Program: 5:30 - 7:00 pm EDT 

    Join us for a discussion of:

    • Treating patients with osteoporosis during the COVID-19 pandemic
    • The role of anabolic therapy in the treatment of osteoporosis and fracture
    • Identification, prevention and treatment of bone loss following bariatric surgery
    • Osteoporosis medication holidays – considerations, indications and duration

    This course is a virtual live CME-certified Ancillary Symposium to be presented at ENDO 2021. This educational activity is supported by an independent medical educational grant from Amgen, Inc. This ancillary symposium is developed through the Endocrine Society’s Special Programs Committee (SPC).




    • CLAIM CME 



    Learning Objectives

    Upon successful completion these educational sessions, participants should be better able to:

    • Discuss how estrogen inhibits bone resorption and regulates bone formation in men
    • Recognize impending fractures and evaluate patients after they have sustained an atypical femoral fracture
    • Assess patient management of glucocorticoid-induced osteoporosis
    • Apply current guidelines for and analyze patient adherence to osteoporosis therapy

    Additional Information

    Target Audience: 
    Clinical researcher
    Scientific researcher
    Nurse/Nurse practitioner
    Physician assistant
    Allied health professional
    Competency Area: 
    Patient Care and Procedural Skills
    Medical Knowledge
    Systems-based Practice
    Topic Area: 
    Bone and Calciotropic Hormones
    Level of Outcomes: 
    Level 1 (Participation)
    Level 2 (Satisfaction)
    Level 3A (Learning: Declarative Knowledge (Knows))
    Level 3B (Learning: Procedural Knowledge (Knows How))
    Level 4 (Learning: Competence (Shows How))
    Activity summary
    Available credit: 
    • 1.50 ABIM MOC
    • 1.50 AMA PRA Category 1 Credits
    • 1.50 CME Certificate of Participation
    Course opens: 
    Course expires: 

    5:30 – 5:35 PM | Introduction, Pre-Test Polling | Kendall F. Moseley, MD

    5:35 – 5:55 PM | Treating Patients with Osteoporosis During the COVID-19 Pandemic | Matthew T. Drake, MD, PhD

    5:55 – 6:15 PM | The Role of Anabolic Therapy in the Management of Osteoporosis and Fracture | Dolores M. Shoback, MD

    6:15 – 6:35 PM | Osteoporosis Medication Holidays – Considerations, Indications and Duration | Nelson B. Watts, MD

    6:45 – 7:00 PM | Closing Remarks, Post-Test Polling, Q&A Session | All Faculty


    Kendall F. Moseley, MD - Program Chair
    Assistant Professor of Medicine
    Division of Endocrinology, Diabetes & Metabolism
    The Johns Hopkins Hospital Baltimore, MD

    Matthew T. Drake, MD, PhD
    Associate Professor Mayo Clinic
    Rochester, MN

    Dolores M. Shoback, MD
    Professor of Medicine
    UCSF/VA Medical Center
    San Francisco, CA

    Nelson B. Watts, MD
    Director of Osteoporosis and Bone Health Services
    Mercy Health
    Cincinnati, OH


    As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.


    The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

    The following faculty reported relevant financial relationships:
    Nelson B. Watts, MD: Speaker, Amgen Inc, Radius Health, Inc.

    The following faculty reported no relevant financial relationships: 
    Matthew T. Drake, MD, PhD; Kendall F. Moseley, MD; Dolores M. Shoback, MD

    The following SPC Committee members reported financial relationships:

    • Andjela T. Drincic, MD: Advisory Board Member, Corcept
    • Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
    • Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member
    • Amy Rothberg, MD: Spouse, consultant of Merck
    • Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

    The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

    The following SPC members reported no relevant financial relationships:

    Beret Ann Casey, MD; Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

    The staff involved in the development of this CME activity reported no relevant financial relationships.



    The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


    When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


    The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


    The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


    This educational activity is supported by an independent medical educational grant from Amgen, Inc.

    The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    AMA PRA Category 1 Credit:

    The Endocrine Society designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

    Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

    Maintenance of Certification (MOC):

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Available Credit

    • 1.50 ABIM MOC
    • 1.50 AMA PRA Category 1 Credits
    • 1.50 CME Certificate of Participation